SkinBioTherapeutics is a life science company focused on skin health. The Company’s proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine O’Neill and Professor Andrew McBain at The University of Manchester. The SkinBioTherapeutics platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, improve repair and reduce bacterial load. SkinBioTherapeutics is targeting three specific skin healthcare sectors; cosmetics, infection control, and eczema. In each of these areas, SkinBioTherapeutics plans to exemplify its technology in human studies. The most advanced programme is focused on the application of the SkinBiotix® platform in managing sensitive skin in the cosmetics industry. The business strategy is to partner and out-license its programmes at the proof of concept. SkinBioTherapeutics plc was admitted to London's AIM on 5th April 2017, raising £4.5m.
View Top Employees from SkinBioTherapeutics PLCWebsite | http://www.skinbiotherapeutics.com |
Revenue | $5 million |
Employees | 10 (6 on RocketReach) |
Founded | 2015 |
Phone | +44 161 468 2760 |
Technologies |
JavaScript,
HTML,
PHP
+17 more
(view full list)
|
Industry | Biotechnology, Manufacturing General, Manufacturing |
Competitors | BioHive, Labskin - scientifically validated tests on lab-grown skin, Plasticell Limited |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies, NAICS Code 32541 Companies |
Looking for a particular SkinBioTherapeutics PLC employee's phone or email?
The SkinBioTherapeutics PLC annual revenue was $5 million in 2024.
Manprit Randhawa is the CFO of SkinBioTherapeutics PLC.
6 people are employed at SkinBioTherapeutics PLC.
The NAICS codes for SkinBioTherapeutics PLC are [3254, 325, 32, 32541].
The SIC codes for SkinBioTherapeutics PLC are [28, 283].